University of Sussex
Browse
__smbhome.uscs.susx.ac.uk_sf356_Desktop_Oplustil O'Connor et al_AZD2461_Cancer Research_Final_15 Dec 2015.pdf (537.91 kB)

The PARP inhibitor AZD2461 provides insights into the role of PARP3 inhibition for both synthetic lethality and tolerability with chemotherapy in preclinical models

Download (537.91 kB)
journal contribution
posted on 2023-06-21, 06:02 authored by Stuart Rulten, Keith CaldecottKeith Caldecott
The PARP inhibitor AZD2461 was developed as a next-generation agent following olaparib, the first PARP inhibitor approved for cancer therapy. In BRCA1-deficient mouse models, olaparib resistance predominantly involves overexpression of P-glycoprotein,so AZD2461 was developed as a poor substrate for drug transporters. Here we demonstrate the efficacy of this compound against olaparib-resistant tumors that overexpress P-glycoprotein. In addition, AZD2461 was better tolerated in combination with chemotherapy than olaparib in mice, which suggests that AZD2461 could have significant advantages over olaparib in the clinic. However, this superior toxicity profile did not extend to rats. Investigations of this difference revealed a differential PARP3 inhibitory activity for each compound and a higher level of PARP3 expression in bone marrow cells from mice as compared with rats and humans. Our findings have implications for the use of mouse models to assess bone marrow toxicity for DNA-damaging agents and inhibitors of the DNA damage response. Finally, structural modeling of the PARP3-active site with different PARP inhibitors also highlights the potential to develop compounds with different PARP family member specificity profiles for optimal antitumor activity and tolerability.

Funding

Characterisation of the Role of the PARP-3 During DNA Double-Strand Break Repair; G0261; CANCER RESEARCH UK; C6563/A13078

History

Publication status

  • Published

File Version

  • Accepted version

Journal

Cancer Research

ISSN

0008-5472

Publisher

American Association for Cancer Research

Issue

20

Volume

76

Department affiliated with

  • Sussex Centre for Genome Damage Stability Publications

Research groups affiliated with

  • Genome Damage and Stability Centre Publications

Full text available

  • Yes

Peer reviewed?

  • Yes

Legacy Posted Date

2017-12-20

First Open Access (FOA) Date

2017-12-20

First Compliant Deposit (FCD) Date

2017-12-20

Usage metrics

    University of Sussex (Publications)

    Categories

    No categories selected

    Exports

    RefWorks
    BibTeX
    Ref. manager
    Endnote
    DataCite
    NLM
    DC